Tounjian Advisory Partners’s Bristol-Myers Squibb BMY Stock Holding History

Tounjian Advisory Partners’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.47K	Buy	+43	New	+$2.47K	﹤0.01%	554

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Pzena Investment Management New York $34.1B AUM 23.81% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Tounjian Advisory Partners's BMY Position: Q2 2026 in Review

Tounjian Advisory Partners opened a new position in Bristol-Myers Squibb (BMY) in Q2 2026: 43 shares worth $2.47K. The stake represents ﹤0.01% of the portfolio and ranks #554 among its holdings.

1,717 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Tounjian Advisory Partners held 43 shares of Bristol-Myers Squibb worth $2.47K as of Q2 2026.
Bristol-Myers Squibb was a new Tounjian Advisory Partners position in Q2 2026.
Bristol-Myers Squibb made up ﹤0.01% of Tounjian Advisory Partners's portfolio in Q2 2026, its #554 holding.
1,717 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Tounjian Advisory Partners's 13F filing for Q2 2026, filed 7 Aug 2026.